Arcus Ventures

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Cleave Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2010. The company focuses on developing novel small-molecule drugs that target valosin-containing protein and other protein-degradation pathways critical for the survival of cancer cells. By creating enzyme inhibitors designed to disrupt these pathways, Cleave Therapeutics aims to address both oncological and neurodegenerative diseases. Through its innovative approach to drug discovery, the company seeks to provide effective therapeutic solutions that enhance patient outcomes in the fight against cancer.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

XTuit Pharmaceuticals, Inc., established in 2011 and headquartered in Waltham, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. The company focuses on creating pharmaceutical preparations for diagnosing and treating oncological, tumor, and inflammatory diseases by pursuing novel approaches that target the tumor microenvironment. Its drug development pipeline and clinical biomarker platform aim to create drugs that inhibit extracellular matrix synthesis and stabilization, and silence activated stromal cells through pleiotropic mechanisms.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. Its leading products include envafolimab, an investigational PD-L1 single-domain antibody currently in pivotal trials for soft tissue sarcoma, and TRC102, a small molecule drug candidate in Phase II trials for lung cancer. Additionally, TRC253, designed for metastatic castration-resistant prostate cancer, is in Phase II development, while TJ004309, a CD73 antibody, is undergoing Phase I trials for solid tumors. TRACON operates a cost-efficient, contract research organization-independent product development platform and actively seeks partnerships with companies outside the U.S. to enhance regulatory and clinical development and commercialization efforts in the U.S. The company was founded in 2004 and was formerly known as Lexington Pharmaceuticals, Inc. before rebranding in 2005.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

Oncoscope, Inc. is a medical device company based in Durham, North Carolina, founded in 2006. The company specializes in the development of optical imaging systems that focus on epithelial tissues found in various parts of the body, including the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder. These advanced systems deliver in vivo measurements of cell nuclei's diameter and density, offering valuable insights into tissue microstructure for clinical applications.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

MI Bioresearch is a specialty contract research organization (CRO) providing in vivo preclinical imaging services. With a proven track record of imaging and drug discovery expertise, the company enhances preclinical and translational research through its in vivo pharmaco-IMAGING platform. This combination of traditional pharmacology and innovative imaging includes MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and fluorescence molecular tomography) tools to quantitatively measure the response to therapy at anatomical, functional and molecular levels. Molecular Imaging also provides supportive in vitro services. They have performed over 2000 cell line based traditional oncology studies and over 500 imaging enhanced studies since their founding in 2003.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. Its leading products include envafolimab, an investigational PD-L1 single-domain antibody currently in pivotal trials for soft tissue sarcoma, and TRC102, a small molecule drug candidate in Phase II trials for lung cancer. Additionally, TRC253, designed for metastatic castration-resistant prostate cancer, is in Phase II development, while TJ004309, a CD73 antibody, is undergoing Phase I trials for solid tumors. TRACON operates a cost-efficient, contract research organization-independent product development platform and actively seeks partnerships with companies outside the U.S. to enhance regulatory and clinical development and commercialization efforts in the U.S. The company was founded in 2004 and was formerly known as Lexington Pharmaceuticals, Inc. before rebranding in 2005.

Vascular Pathways is a Naples, Florida-based medical device company focused on commercializing the Rapid IntraVascular Start catheter, an FDA-cleared device that enables rapid, safe, and successful peripheral IV insertion. Founded by Amir Belson, M.D., the company aims to bring vascular access innovations to clinical practice.

Clear Vascular, Inc. is a clinical-stage company established in 2005 by Dr. Gilbert Gonzales, focused on developing innovative pharmaceutical products for the treatment of cardiovascular diseases. The company's primary product, Tin-Annexin, is designed for both imaging and therapeutic intervention of inflammatory tissues, specifically targeting vulnerable and unstable plaque. This dual functionality allows for earlier treatment initiation, significantly enhancing the likelihood of successful patient outcomes. Clear Vascular's products leverage tin-117m, developed through collaborations with the US Department of Energy and Brookhaven National Laboratory, utilizing advanced production methods to ensure high specific activity. The innovative approaches to tin-117m production, including techniques involving alpha particles and cadmium-116 targets, have been validated through extensive pre-clinical and clinical trials, confirming the efficacy of imaging and treating vascular inflammatory diseases.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Oncoscope, Inc. is a medical device company based in Durham, North Carolina, founded in 2006. The company specializes in the development of optical imaging systems that focus on epithelial tissues found in various parts of the body, including the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder. These advanced systems deliver in vivo measurements of cell nuclei's diameter and density, offering valuable insights into tissue microstructure for clinical applications.

Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

MacroGenics is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer treatment. Its pipeline includes Margetuximab targeting HER2-expressing tumors, Flotetuzumab for acute myeloid leukemia, and other immuno-oncology product candidates such as MGA012, MGD013, MGD019, and Enoblituzumab. The company also develops combination therapies like MGD009 with MGA012, and antibody drug conjugates like MGC018 targeting B7-H3.

Genta Incorporated is a biopharmaceutical company that specializes in the development and commercialization of cancer treatment drugs. With a focus on identifying and advancing innovative therapies, Genta has established a diverse portfolio of proprietary products at different stages of clinical development. Some of the key drugs in the Company's pipeline include Ganite (gallium nitrate injection), tesetaxel, and oral gallium. By leveraging its expertise in oncology research and drug development, Genta aims to address the unmet medical needs of cancer patients and improve outcomes in the field of oncology.